Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, long-acting Factor XI (FXI) small...
Enabled by WuXi Biologics' industry-leading integrated technology platform, velaglucerase-beta for injection has successfully advanced from concept to ...
Shanghai Ark Biopharmaceutical announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of idiopathic...
The Asthma and Allergy Foundation of America (AAFA) appreciates the President’s Executive Order calling attention to America’s persistent pro...
Silo Pharma, Inc., a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced that it has e...
Invenra Inc., a biotechnology company specializing in the discovery and development of multispecific antibodies, announced that its collaboration par...
Acquisition adds Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases Strengthens QIAGEN Digital Insigh...
Eurofins Viracor, a leading specialty diagnostics laboratory, is proud to announce a groundbreaking advancement in respiratory infection diagnostics with...
ANPD001 was well tolerated with no major safety issues in low-dose cohort Patients showed early improvements in patient-reported and clinician-re...
- Patients treated with VCN-01 (zabilugene almadenorepvec) plus standard gemcitabine/nab-paclitaxel chemotherapy had increased overall survival, progress...
600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pa...
Exclusive licensing and R&D collaboration accelerate the development of a novel gene vector platform for precision gene therapy in Hepatocellular Car...
Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS...
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases, toda...
© 2025 Biopharma Boardroom. All Rights Reserved.
